Barely Significant
← all excerpts

Immunomodulatory potential of dexmedetomidine in perioperative pain management for patients with cancer.

Cancer Pathog Ther · 2025 · PMC12277841 · PMID 40697508

1
hedged sentence
closest p
boldest claim

The sentences

showed a trendno p-value reported
14 In colorectal cancer, a follow-up study of 60 patients who received intraoperative DEX (1 μg/kg loading dose, followed by 0.3 μg·kg −1 ·h −1 infusion) showed a trend toward improved overall and disease-free survival, although these differences were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.